Akebia Therapeutics, Inc. (AKBA)
| Previous Close | 1.1400 |
| Open | 1.1300 |
| Bid | 1.1500 x 200 |
| Ask | 1.1600 x 200 |
| Day's Range | 1.1200 - 1.1750 |
| 52 Week Range | 0.7800 - 2.4800 |
| Volume | |
| Avg. Volume | 5,200,304 |
| Market Cap | 241.895M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.
- PR Newswire
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2024. Akebia is launching Vafseo® (vadadustat) tablets, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months, which will be available in J
- PR Newswire
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets.
